Variability of sorafenib toxicity and exposure over time: A pharmacokinetic/pharmacodynamic analysis

Oncologist

Volumn 17, Issue 9, 2012, Pages 1204-1212

  Boudou Rouquette, Pascaline ^a   Ropert, Stanislas ^a   Mir, Olivier ^a   Coriat, Romain ^a,b   Billemont, Bertrand ^a,d   Tod, Michel ^e,f   Cabanes, Laure ^a,b   Franck, Nathalie ^b   Blanchet, Benoit ^a,c   Goldwasser, FrançOis ^a  

^a Center for Research on Angiogenesis Inhibitors   (France)

^b Department of Gastroenterology ^*  (France)

^c Institut Cochin   (France)

^d INSTITUT JEAN GODINOT   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f UNIVERSITÉ DE LYON   (France)

Author keywords

Angiogenesis inhibitors; Population pharmacokinetics; Sorafenib; Therapeutic drug monitoring; Toxicity; VEGF A

Indexed keywords

ALBUMIN; BILIRUBIN; C REACTIVE PROTEIN; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLEEDING; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DARIER DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG TOXICITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPEPSIA; DYSPHONIA; DYSPNEA; ERYTHEMA; FEMALE; GENDER; HAND FOOT SYNDROME; HEART DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; PNEUMATOSIS INTESTINALIS; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION; XEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZENESULFONATES; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PYRIDINES; RETROSPECTIVE STUDIES; TOXICITY TESTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866563270     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0439     Document Type: Article

References (37)

1. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844.
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;11:125-134.
3. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 24:378-390.
4. Gupta-Abramson VTA, Nellore A, Puttaswamy K et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;10:4714-4719.
5. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684.
6. McDermott DF, Sosman JA, Gonzalez R et al. Double- blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J Clin Oncol 2008;26:2178-2185.
7. Hauschild A, Agarwala SS, Trefzer U et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27: 2823-2830.
8. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-3140.
9. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-5480.
10. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
11. Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116:1272-1280.
12. La Vine DB, Coleman TA, Davis CH et al. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 2010;33:217-220.
13. Riechelmann RP, Chin S, Wang L et al. Sorafenib for metastatic renal cancer: The Princess Margaret experience. Am J Clin Oncol 2008;31:182-187.
14. National Cancer Institute. Common terminology criteria for adverse events. Bethesda, MD: National Institutes of Health; 2006.
15. National Cancer Institute. Common terminology criteria for adverse events. Bethesda, MD: National Institutes of Health; 2009.
16. Blanchet B, Billemont B, Cramard J et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009;49: 1109-1114.
17. Hornecker M, Blanchet B, Billemont B et al. Saturable absorption of sorafenib in patients with solid tumors: A population model. Invest New Drugs 2011 Oct 18 [Epub ahead of print].
18. Coriat R, Ropert S, Mir O et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 2011; 29:1090-1093.
19. Franck N, Barete S, Moguelet P et al. Spiny follicular hyperkeratosis eruption: A new cutaneous adverse effect of sorafenib. J Clin Oncol 28: e640-642.
20. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. NEngl J Med 1999;341:2061-2067.
21. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: Subset analysis from a randomized trial. J Natl Cancer Inst 2008;100: 1454-1463.
22. Zhang L, Zhou Q, Ma L et al. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 2011;36:344-350.
23. Hutson TE, Bellmunt J, Porta C et al. Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. Eur J Cancer 2010;46:2432-2440.
24. Strumberg D, Awada A, Hirte H et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006;42:548-556.
25. Azad NS, Aragon-Ching JB, Dahut WL et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009;15: 1411-1416.
26. Iijima M, Fukino K, Adachi M et al. Sorafenib-associated hand-foot syndrome in Japanese patients. J Dermatol 2011;38:261-266.
27. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors: A review. Eur J Cancer 2006;42:3127-3139.
28. Bellmunt J, Gonzalez-Larriba JL, Prior C et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatinbased chemotherapy: Baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011;22:2646-2653.
29. van Erp NP, Eechoute K, van der Veldt AA et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009;27:4406-4412.
30. van der Veldt AA, Boven E, Helgason HH et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99:259-265.
31. Kalantari HR. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2009;101:1222-1223.
32. Judson I, Ma P, Peng B et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005;55:379-386.
33. Burger H, van Tol H, Brok M et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005;4:747-752.
34. Semrad TJ, Gandara DR, Lara PN, Jr. Enhancing the clinical activity of sorafenib through dose escalation: Rationale and current experience. Ther Adv Med Oncol 2011;3:95-100.
35. Pécuchet N, Kerob D, Billemont B et al. Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma. J Clin Oncol 2010;28:15s.
36. Pressiani LR, Boni C, Labianca R et al. Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. J Clin Oncol 2011; 29.
37. Gore RJJ, Ravaud A, Kuczyk M et al. Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). J Clin Oncol 2011;29 (Suppl.):Abstract 4609.